文献速递慢性肾脏病

尿调节素及其与尿液代谢物的关联:德国慢性肾脏病研究

Uromodulin and its association with urinary metabolites: the German Chronic Kidney Disease Study.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

在德国慢性肾脏病研究(N=4628)中,横断面分析发现与尿和血清尿调节素相关的尿液代谢物,并构建加权代谢物评分,评估6.5年不良肾脏事件风险。较高的血清尿调节素及血清代谢物评分与较低的不良肾脏事件风险相关,尿液指标方向相同但未达统计学显著。

要点

  • 血清尿调节素较高与不良肾脏事件风险降低相关(HR=0.74)。
  • 血清代谢物评分较高与不良肾脏事件风险降低相关(HR=0.73)。
  • 尿液尿调节素及尿液代谢物评分与不良肾脏事件关联方向相同但未达统计学显著。

核心结论

  • 血清尿调节素和血清代谢物评分与慢性肾脏病患者较低的不良肾脏事件风险相关。
  • 较高的血清尿调节素和血清代谢物评分可能反映更多功能性肾单位,从而降低不良肾脏结局风险。

研究设计与样本

  • 德国慢性肾脏病研究(N=4628)是一项前瞻性观察性研究,进行横断面分析。
  • 测量尿和血清尿调节素水平及607种尿液代谢物,构建加权代谢物评分,评估6.5年不良肾脏事件时间。

主要发现

  • 与尿调节素横断面相关的代谢物包括色氨酸代谢的氨基酸、脂质和核苷酸。
  • 血清代谢物评分较高与较低的不良肾脏事件风险相关(HR=0.73,95%CI 0.64;0.82,P=7.45e-07)。
  • 血清尿调节素较高与较低的不良肾脏事件风险相关(HR=0.74,95%CI 0.63;0.87,P=2.32e-04)。
  • 尿液尿调节素和尿液代谢物评分与不良肾脏事件的关联方向相同但未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The progression of chronic kidney disease (CKD), a global public health burden, is accompanied by a declining number of functional nephrons. Estimation of remaining nephron mass may improve assessment of CKD progression. Uromodulin has been suggested as a marker of tubular mass. We aimed to identify metabolites associated with uromodulin concentrations in urine and serum to characterize pathophysiologic alterations of metabolic pathways to generate new hypotheses regarding CKD pathophysiology. METHODS: We measured urinary and serum uromodulin levels (uUMOD, sUMOD) and 607 urinary metabolites and performed cross-sectional analyses within the German Chronic Kidney Disease study (N = 4628), a prospective observational study. Urinary metabolites significantly associated with uUMOD and sUMOD were used to build weighted metabolite scores for urine (uMS) and serum uromodulin (sMS) and evaluated for time to adverse kidney events over 6.5 years. RESULTS: Metabolites cross-sectionally associated with uromodulin included amino acids of the tryptophan metabolism, lipids and nucleotides. Higher levels of the sMS [hazard ratio (HR) = 0.73 (95% confidence interval 0.64; 0.82), P = 7.45e-07] and sUMOD [HR = 0.74 (95% confidence interval 0.63; 0.87), P = 2.32e-04] were associated with a lower risk of adverse kidney events over time, whereas uUMOD and uMS showed the same direction of association but were not significant. CONCLUSIONS: We identified urinary metabolites associated with urinary and serum uromodulin. The sUMOD and the sMS were associated with lower risk of adverse kidney events among CKD patients. Higher levels of sUMOD and sMS may reflect a higher number of functional nephrons and therefore a reduced risk of adverse kidney outcomes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Bächle H, Sekula P, Schlosser P, et al. Uromodulin and its association with urinary metabolites: the German Chronic Kidney Disease Study. Nephrol Dial Transplant. 2023. PMID: 35612992. doi:10.1093/ndt/gfac187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。